Serge Jabbour

TitleProfessor
InstitutionThomas Jefferson University
DepartmentEndocrinology & Metabolism
Address800 Walnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Guja C, Frías JP, Suchower L, Hardy E, Marr G, Sjöström CD, Jabbour SA. Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Diabetes Ther. 2020 Dec; 11(12):3011-3013. PMID: 33011938.
      Citations:    
    2. Jabbour SA, Frías JP, Ahmed A, Hardy E, Choi J, Sjöström CD, Guja C. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes Care. 2020 Aug 18. PMID: 32816874.
      Citations:    
    3. Guja C, Frías JP, Suchower L, Hardy E, Marr G, Sjöström CD, Jabbour SA. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Diabetes Ther. 2020 Apr 18. PMID: 32306296.
      Citations:    
    4. Vilsbøll T, Ekholm E, Johnsson E, Garcia-Sanchez R, Dronamraju N, Jabbour SA, Lind M. Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52?weeks as add-on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, phase 3 trial. Diabetes Obes Metab. 2020 Jan 31. PMID: 32003150.
      Citations:    
    5. Hazan E, Griffin TD, Jabbour SA, Keller MS. Scleromyxedema in a patient with thyroid disease: an atypical case or a case for revised criteria? Cutis. 2020 Jan; 105(1):E6-E10. PMID: 32074156.
      Citations:    
    6. Gastaldelli A, Repetto E, Guja C, Hardy E, Han J, Jabbour SA, Ferrannini E. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab. 2019 Nov 06. PMID: 31692226.
      Citations:    
    7. Ferrannini E, Baldi S, Frías JP, Guja C, Hardy E, Repetto E, Jabbour SA, DeFronzo RA. Hormone-Substrate Changes with Exenatide Plus Dapagliflozin Versus Each Drug Alone: The Randomized, Active-Controlled DURATION-8 Study. Diabetes Obes Metab. 2019 Aug 30. PMID: 31469220.
      Citations:    
    8. Vilsbøll T, Ekholm E, Johnsson E, Dronamraju N, Jabbour S, Lind M. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial. Diabetes Care. 2019 Aug; 42(8):1464-1472. PMID: 31167892.
      Citations:    
    9. Postolache TT, Del Bosque-Plata L, Jabbour S, Vergare M, Wu R, Gragnoli C. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am J Med Genet B Neuropsychiatr Genet. 2019 Apr; 180(3):186-203. PMID: 30729689.
      Citations:    
    10. Jabbour SA, Frías JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes Care. 2018 10; 41(10):2136-2146. PMID: 30082326.
      Citations:    
    11. Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N, Hansen L, Thorén F, Langkilde AM. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care. 2018 09; 41(9):1938-1946. PMID: 30026335.
      Citations:    
    12. Frías JP, Hardy E, Ahmed A, Öhman P, Jabbour S, Wang H, Guja C. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. Diabetes Obes Metab. 2018 Mar 23. PMID: 29573139.
      Citations:    
    13. Cunningham AT, Delgado DJ, Jackson JD, Crawford AG, Jabbour S, Lieberthal RD, Diaz V, LaNoue M. Evaluation of an Ongoing Diabetes Group Medical Visit in a Family Medicine Practice. J Am Board Fam Med. 2018 Mar-Apr; 31(2):279-281. PMID: 29535245.
      Citations:    
    14. Guja C, Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diabetes Obes Metab. 2018 Feb 23. PMID: 29473704.
      Citations:    
    15. Jabbour SA, Frías JP, Guja C, Hardy E, Ahmed A, Öhman P. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes Obes Metab. 2018 Jan 05. PMID: 29316164.
      Citations:    
    16. Caspard H, Jabbour S, Hammar N, Fenici P, Sheehan JJ, Kosiborod M. Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014. Diabetes Obes Metab. 2018 Mar; 20(3):667-671. PMID: 29077244.
      Citations:    
    17. Shohat N, Tarabichi M, Tischler EH, Jabbour S, Parvizi J. Serum Fructosamine: A Simple and Inexpensive Test for Assessing Preoperative Glycemic Control. J Bone Joint Surg Am. 2017 Nov 15; 99(22):1900-1907. PMID: 29135663.
      Citations:    
    18. Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab. 2018 Mar; 20(3):620-628. PMID: 28950419.
      Citations:    
    19. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017 10 17; 318(15):1460-1470. PMID: 29049653.
      Citations:    
    20. Jabbour S. Durability of response to dapagliflozin: a review of long-term efficacy and safety. Curr Med Res Opin. 2017 Jul 31; 1-12. PMID: 28699798.
      Citations:    
    21. Warren ML, Chaykin LB, Jabbour S, Sheikh-Ali M, Hansen CT, Nielsen TSS, Norwood P. Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. Clin Diabetes. 2017 Apr; 35(2):90-95. PMID: 28442823.
      Citations:    
    22. Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017 Jun; 19(6):858-865. PMID: 28124817.
      Citations:    
    23. Pappu R, Jabbour SA, Reginato AM, Reginato AJ. Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism. Clin Rheumatol. 2017 Mar; 36(3):735. PMID: 28091807.
      Citations:    
    24. Pappu R, Jabbour SA, Regianto AM, Reginato AJ. Musculoskeletal manifestations of primary hyperparathyroidism. Clin Rheumatol. 2016 Dec; 35(12):3081-3087. PMID: 27815654.
      Citations:    
    25. Frías JP, Guja C, Hardy E, Ahmed A, Dong F, Öhman P, Jabbour SA. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016 Dec; 4(12):1004-1016. PMID: 27651331.
      Citations:    
    26. Jabbour S. Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes? Expert Opin Pharmacother. 2014 Dec; 15(18):2751-3. PMID: 25346092.
      Citations:    
    27. Burkhart RA, Gerber SM, Tholey RM, Lamb KM, Somasundaram A, McIntyre CA, Fradkin EC, Ashok AP, Felte RF, Mehta JM, Rosato EL, Lavu H, Jabbour SA, Yeo CJ, Winter JM. Incidence and severity of pancreatogenic diabetes after pancreatic resection. J Gastrointest Surg. 2015 Feb; 19(2):217-25. PMID: 25316483.
      Citations:    
    28. Mehta JM, Miller JL, Cannon AJ, Mardekian SK, Kenyon LC, Jabbour SA. Ovarian leydig cell hyperplasia: an unusual case of virilization in a postmenopausal woman. Case Rep Endocrinol. 2014; 2014:762745. PMID: 25045549.
      Citations:    
    29. Jabbour SA, Jabbour SA. SGLT2 inhibitors to control Glycemia in type 2 diabetes mellitus: a new approach to an old problem. Postgrad Med. 2014 Jan; 126(1):111-7. PMID: 24393758.
      Citations:    
    30. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care. 2014 Mar; 37(3):740-50. PMID: 24144654.
      Citations:    
    31. Jabbour S, Miller JL. Collaboration designed to increase translation of diabetes research outcomes into clinical practice. Clin Ther. 2013 May; 35(5):712-3. PMID: 23688535.
      Citations:    
    32. Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med. 2012 Jul; 124(4):62-73. PMID: 22913895.
      Citations:    
    33. Intenzo C, Jabbour S, Miller JL, Ahmed I, Furlong K, Kushen M, Kim SM, Capuzzi DM. Subclinical hyperthyroidism: current concepts and scintigraphic imaging. Clin Nucl Med. 2011 Sep; 36(9):e107-13. PMID: 21825836.
      Citations:    
    34. Bischoff LA, Jabbour SA, Miller JL. Exenatide once weekly in type 2 diabetes mellitus. Expert Opin Pharmacother. 2011 Jun; 12(8):1297-1303. PMID: 21548720.
      Citations:    
    35. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. Curr Opin Endocrinol Diabetes Obes. 2011 Apr; 18(2):148-52. PMID: 21522002.
      Citations:    
    36. Velasco G, Savarese V, Sandorfi N, Jimenez SA, Jabbour S. 46, XX SRY-positive male syndrome presenting with primary hypogonadism in the setting of scleroderma. Endocr Pract. 2011 Jan-Feb; 17(1):95-8. PMID: 20841307.
      Citations:    
    37. Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011 Jan; 123(1):15-23. PMID: 21293080.
      Citations:    
    38. Jabbour SA. Skin manifestations of hormone-secreting tumors. Dermatol Ther. 2010 Nov-Dec; 23(6):643-50. PMID: 21054708.
      Citations:    
    39. Ahmed I, Jabbour SA. Visual vignette. Endocr Pract. 2009 Nov-Dec; 15(7):766. PMID: 19625238.
      Citations:    
    40. Critchell CD, Savarese V, Callahan A, Aboud C, Jabbour S, Marik P. Accuracy of bedside capillary blood glucose measurements in critically ill patients. Intensive Care Med. 2007 Dec; 33(12):2079-84. PMID: 17763842.
      Citations:    
    41. Intenzo CM, Jabbour S, Lin HC, Miller JL, Kim SM, Capuzzi DM, Mitchell EP. Scintigraphic imaging of body neuroendocrine tumors. Radiographics. 2007 Sep-Oct; 27(5):1355-69. PMID: 17848696.
      Citations:    
    42. Varghese P, Gleason V, Sorokin R, Senholzi C, Jabbour S, Gottlieb JE. Hypoglycemia in hospitalized patients treated with antihyperglycemic agents. J Hosp Med. 2007 Jul; 2(4):234-40. PMID: 17702035.
      Citations:    
    43. Rubin DJ, Moshang J, Jabbour SA. Diabetes knowledge: are resident physicians and nurses adequately prepared to manage diabetes? Endocr Pract. 2007 Jan-Feb; 13(1):17-21. PMID: 17360296.
      Citations:    
    44. Jabbour SA. Endocrinology in dermatology. Clin Dermatol. 2006 Jul-Aug; 24(4):235-6. PMID: 16828403.
      Citations:    
    45. Jabbour SA, Davidovici BB, Wolf R. Rare syndromes. Clin Dermatol. 2006 Jul-Aug; 24(4):299-316. PMID: 16828412.
      Citations:    
    46. Rosenberg DE, Jabbour SA, Goldstein BJ. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes Obes Metab. 2005 Nov; 7(6):642-53. PMID: 16219008.
      Citations:    
    47. Intenzo CM, Jabbour S, Dam HQ, Capuzzi DM. Changing concepts in the management of differentiated thyroid cancer. Semin Nucl Med. 2005 Oct; 35(4):257-65. PMID: 16150246.
      Citations:    
    48. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004 Apr; 20(4):565-72. PMID: 15119994.
      Citations:    
    49. Intenzo CM, dePapp AE, Jabbour S, Miller JL, Kim SM, Capuzzi DM. Scintigraphic manifestations of thyrotoxicosis. Radiographics. 2003 Jul-Aug; 23(4):857-69. PMID: 12853661.
      Citations:    
    50. Wu X, Hardy VE, Joseph JI, Jabbour S, Mahadev K, Zhu L, Goldstein BJ. Protein-tyrosine phosphatase activity in human adipocytes is strongly correlated with insulin-stimulated glucose uptake and is a target of insulin-induced oxidative inhibition. Metabolism. 2003 Jun; 52(6):705-12. PMID: 12800095.
      Citations:    
    51. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003; 4(5):315-31. PMID: 12688837.
      Citations:    
    52. Dagher HN, Aboujaoude ZC, Jabbour SA. Chronic urticaria: an unusual initial manifestation of primary hyperparathyroidism. Endocr Pract. 2002 Jan-Feb; 8(1):47-9. PMID: 11939760.
      Citations:    
    Jabbour's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (146)
    Explore
    _
    Co-Authors (25)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _